| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| 05/01/2026 | ±2.4% | -4.1% | under-priced |
| 01/30/2026 | ±1.8% | +0.3% | over-priced |
| 10/31/2025 | ±2.3% | -2.1% | over-priced |
| 04/24/2025 | ±3.4% | +10.1% | under-priced |
| 01/31/2025 | ±2.9% | -8.3% | under-priced |
| 10/25/2024 | ±1.9% | +7.1% | under-priced |
| 04/26/2024 | ±2.0% | +18.9% | under-priced |
| 01/25/2024 | ±2.8% | +8.5% | under-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q4 FY2026 | $2.64 | $1.5B | $383M |
| Q3 FY2026 | $2.74 | $1.4B | $399M |
| Q2 FY2026 | $2.68 | $1.4B | $393M |
| Q1 FY2026 | $2.37 | $1.3B | $349M |
ResMed Inc. (RMD) reports in 46 days, with the next report estimated for 10/28/2026. Across the last 8 reports, options priced an average ±2.4% earnings move while the stock actually moved 7.4% on average — the market has tended to under-price RMD's earnings risk. Fundamentals into the print: EPS up 2.3% year-over-year, revenue up 8.6%. QuantLogix's live 5-factor engine currently reads RMD as a underweight at 43/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →